Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026
[173 Pages Report] The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.
To know about the assumptions considered for the study, download the pdf brochure
COVID-19 impact on the PDX models market
In 2020, it was projected that the PDX models market would be negatively impacted due to reduced productivity in life science organizations attributed to country-wise lockdowns, the disruption of clinical trials, and reduction in pharma R&D deals in therapeutic areas apart from COVID-19. For instance, According to GEP Worldwide, more than 1,200 clinical trials across the globe were disrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the suspension of patient enrolment. Trials involving respiratory disease, oncology, ID/anti-infectives, and cardiovascular disease were the worst-hit during this time. The market is projected to grow at a steady rate after 2022, as the COVID-19 impact is projected to diminish.
Global PDX models Market Dynamics
DRIVER: Growing demand for personalized medicine
Personalized medicine is the process of developing tailored medications to provide individualized treatment and care based on personal and genetic variations. These medicines are designed through the use of animal models. In this process, immunodeficient models are transplanted with human tissues, and the disease expressed is recorded. This is followed by treating the model with drugs/gene therapies to find the most suitable treatment, thus generating suitable or personalized medicines.
The development of therapies for key diseases such as cancer has attracted significant attention. Currently, cancer is a major burden on the healthcare systems across geographies. According to data released by GLOBOCAN in 2020, it is estimated that 19.3 million cases and 10 million cancer deaths occurred in 2020. In vitro and in vivo strategies are being developed to combat the rising prevalence of cancer and offer effective treatments to patients. A significant development in this regard is the emergence of PDX models, as they have high predictive power for the efficacy of standard and novel anti-cancer therapeutics. Owing to this advantage, these models are increasingly being used in preclinical studies.
RESTRAINT: High cost of personalized PDX models
To create personalized PDX models, a piece of the patient’s tumor is implanted and grown in several immunocompromised models. It is then harvested, fragmented, and implanted again in a larger set of models treated with various drugs and drug combinations. Considering the cost of creating and maintaining these models, coupled with the requirement of expensive drugs in these models, PDX experiments can cost thousands of dollars, even in the case of a single patient. Moreover, using PDX models in government-funded basic research can also be cost-prohibitive. These are the major factors limiting the wider adoption of PDX models across the globe.
OPPORTUNITY: Rising demand for humanized PDX models
As xenografts grow well in immunodeficient models, these models are majorly used for PDX model creation. However, these models are not suitable for evaluating stroma-tumor interactions, majorly responsible for tumor growth and progression in a patient. Humanized PDX models help overcome these issues and are gaining popularity in the market.
Immunodeficient mice (such as NOD SCID mice) are now being reconstituted with bone marrow or peripheral blood cells, along with patient tumor implants, to generate humanized xenograft models. These models provide a valuable platform to study the contribution of xenogeneic immune cells to the overall anti-tumor immunity. They also help study immunotherapy drugs aimed at mobilizing the effector arm of the immune system. However, in humanized xenografts, there is a potential risk of graft versus host disease. This limitation can be mitigated by keeping the experimental setup and analysis to a reasonable time frame of 6–10 weeks.
The mice models segment dominated the PDX models market in 2020.
On the basis of type, the PDX models market is broadly segmented into mice models and rat models. In 2020, mice models accounted for the largest share of the PDX models market. This can primarily be attributed to factors such as ease of procurement, ease of manipulation, and the minimum facility requirement for keeping mice models under observation compared to rats is driving their use in the generation of PDX models.
The contract research organizations segment will witness the highest growth during the forecast period.
Based on application, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2020, the contract research organizations segment is expected to register the highest CAGR during the forecast period. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.
North America was the largest regional market for PDX models market in 2020.
Geographically, the PDX model market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2020, North America accounted for the largest share of the PDX models market, followed by Europe and the Asia Pacific. The large share of the North American market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells.
Key Market Players
Key players in the PDX models market include JSR Corporation (Japan), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Oncodesign (France), Charles River Laboratories (US), Hera Biolabs (US), EPO Berlin-Buch (Germany), Envigo (US), Xentech (France), Urosphere (France), and Explora BioLabs (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2019–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD million) |
|
Segments covered |
Type, tumor type, application, end user, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
|
Companies covered |
JSR Corporation (Japan), WuXi AppTec (China), Champions Oncology, Inc. (US), THE JACKSON LABORATORY (US), Charles River Laboratories (US), Oncodesign (France), Envigo (US), Pharmatest Services (Finland), Hera BioLabs (US), EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Abnova Corporation (Taiwan), Genesis Biotechnology Group (US), Explora BioLabs (US), Biocytogen (US), Living Tumor Laboratory (Canada), Bioduro (US), Aragen Life Sciences w.e.f, (US), Shanghai Lide Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), BEIJING IDMO Co. Ltd. (China), and Shanghai ChemPartner Co., Ltd. (China) |
This report categorizes the PDX models market into the following segments and subsegments
PDX models Market, by Type
- Mice Models
- Rat Models
PDX models Market, by Tumor Type
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Hematological Tumor Models
- Other Tumor Models
PDX models Market, by Application
- Preclinical Drug Development
- Biomarker Analysis
- Basic Cancer Research
PDX models Market, by End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutions
PDX models Market, by Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- China
- Japan
- Rest of Asia Pacific (RoAPAC)
- Latin America
- Middle East and Africa
Recent Developments
- In 2019, Charles River Laboratories (US) updated its online Tumor Model Compendium by adding 79 new patient-derived xenografts, ten new cell line-derived xenografts, and 36 new cell line models for several cancer types, including anal, colon, lung, and renal cancer, as well as leukemia and melanoma.
- In November 2019, Envigo (US) acquired the assets of the research models business unit of Horizon Discovery Group plc (UK).
- In September 2018, JSR Corporation (Crown Bioscience Inc.) company announced addition of PDX models of prostate cancer to its product portfolio.
Frequently Asked Questions (FAQ):
What is the impact of COVID-19 on the PDX models Market?
In 2020, it was projected that the PDX models market would be negatively impacted due to reduced productivity in life science organizations attributed to country-wise lockdowns, the disruption of clinical trials, and reduction in pharma R&D deals in therapeutic areas apart from COVID-19. The market is projected to grow at a steady rate after 2022, as the COVID-19 impact is projected to diminish.
Who are the key players in the PDX models Market?
Key players in the PDX models market include JSR Corporation (Japan), WuXi AppTec (China), Champions Oncology, Inc (US), The Jackson Laboratory (US), Oncodesign (France), Charles River Laboratories (US), Hera Biolabs (US), EPO Berlin-Buch (Germany), Envigo (US), Xentech (France), Urosphere (France), and Explora BioLabs (US).
Which type segment dominates in the PDX models market?
The mice models segment accounted for the largest share of the global PDX models market in 2020. This can primarily be attributed to factors such as ease of procurement, ease of manipulation, and the minimum facility requirement for keeping mice models under observation compared to rats is driving their use in the generation of PDX models.
Which end user segment of the global PDX models market is expected to witness the highest growth?
Contract research organizations (CROs) end user segment is expected to witness the highest growth. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.
What is the market for PDX models?
The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 20)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED IN THE REPORT
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 24)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
FIGURE 3 PDX MODELS MARKET: BREAKDOWN OF PRIMARIES
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2020
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
FIGURE 6 PDX MODELS MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 7 PDX MODELS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 34)
FIGURE 9 PDX MODELS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 PDX MODELS MARKET, BY TUMOR TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 PDX MODELS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 12 PDX MODELS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 13 PDX MODELS MARKET: GEOGRAPHIC SNAPSHOT
4 PREMIUM INSIGHTS (Page No. - 38)
4.1 PDX MODELS MARKET OVERVIEW
FIGURE 14 INCREASING SUPPORT FOR CANCER RESEARCH FROM PUBLIC AND PRIVATE SECTORS AND GROWING DEMAND FOR PRECISION MEDICINE ARE KEY GROWTH DRIVERS
4.2 NORTH AMERICA: PDX MODELS MARKET, MARKET SHARE (2020)
FIGURE 15 MICE MODELS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN PDX MODELS MARKET IN 2020
4.3 PDX MODELS MARKET SHARE, BY END USER (2020)
FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED THE LARGEST SHARE OF THE PDX MODELS MARKET IN 2020
4.4 PDX MODELS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO WITNESS THE HIGHEST GROWTH IN THE PDX MODELS MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 41)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 PDX MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 PDX MODELS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Growing demand for personalized medicine
5.2.1.2 Continuous support for cancer research from the public & private sectors
5.2.1.3 Rising pharma R&D
5.2.2 RESTRAINTS
5.2.2.1 High cost of personalized PDX models
5.2.2.2 Stringent guidelines for the use of animal models in cancer research
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for humanized PDX models
5.2.4 CHALLENGES
5.2.4.1 Limitations of PDX models
5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE PDX MODELS MARKET
5.4 TECHNOLOGICAL ANALYSIS
5.5 PRICING ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF PDX MODELS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
FIGURE 20 VALUE CHAIN: CREATION OF PDX MODELS—MAXIMUM VALUE IS ADDED DURING THE IMPLANTATIONS OF TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
5.7 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET
FIGURE 21 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET
TABLE 2 SUPPLY CHAIN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 PDX MODELS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.3.4 Australia
5.9.4 LATIN AMERICA
5.9.5 MIDDLE EAST & AFRICA
5.10 PATENT ANALYSIS
FIGURE 22 PATENTS GRANTED FOR PDX MODELS, JANUARY 2010–DECEMBER 2020
6 PDX MODELS MARKET, BY TYPE (Page No. - 59)
6.1 INTRODUCTION
TABLE 4 PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2 MICE MODELS
6.2.1 EASE OF PROCUREMENT AND WIDE AVAILABILITY OF MICE MODELS DRIVE THE GROWTH OF THIS SEGMENT
TABLE 5 PDX MICE MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 6 NORTH AMERICA: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 7 EUROPE: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 8 ASIA PACIFIC: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 RAT MODELS
6.3.1 FACTORS SUCH AS EASIER SURGICAL MANIPULATION AND LARGER TUMOR SIZE WILL SUPPORT USE OF RAT MODELS
TABLE 9 PDX RAT MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 10 NORTH AMERICA: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 11 EUROPE: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 12 ASIA PACIFIC: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 PDX MODELS MARKET, BY TUMOR TYPE (Page No. - 64)
7.1 INTRODUCTION
TABLE 13 PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
7.2 GASTROINTESTINAL TUMOR MODELS
7.2.1 NEWLY DEVELOPED GASTROINTESTINAL TUMOR MODELS MIMIC THE TUMOR BETTER THAN PREVIOUS MODELS
TABLE 14 GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 15 NORTH AMERICA: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 16 EUROPE: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 ASIA PACIFIC: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 GYNECOLOGICAL TUMOR MODELS
7.3.1 HIGH INCIDENCE OF TARGET CANCERS HAS DRIVEN DEMAND FOR TUMOR MODELS
TABLE 18 GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 19 NORTH AMERICA: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 20 EUROPE: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 21 ASIA PACIFIC: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 RESPIRATORY TUMOR MODELS
7.4.1 RISING PREVALENCE OF LUNG CANCER TO DRIVE MARKET GROWTH
TABLE 22 RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 23 NORTH AMERICA: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 EUROPE: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 25 ASIA PACIFIC: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 UROLOGICAL TUMOR MODELS
7.5.1 COMPANIES ARE FOCUSING ON EXPANDING THEIR PORTFOLIO FOR UROLOGICAL CANCERS
TABLE 26 UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 27 NORTH AMERICA: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 EUROPE: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 29 ASIA PACIFIC: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 HEMATOLOGICAL TUMOR MODELS
7.6.1 NEW STRAINS SUCH AS NSG AND NOG HAVE INCREASED THE LIFE SPAN OF HEMATOLOGICAL TUMOR MODELS
TABLE 30 HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 NORTH AMERICA: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 EUROPE: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 ASIA PACIFIC: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.7 OTHER TUMOR MODELS
TABLE 34 OTHER TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 35 NORTH AMERICA: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 36 EUROPE: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 ASIA PACIFIC: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 PDX MODELS MARKET, BY APPLICATION (Page No. - 76)
8.1 INTRODUCTION
TABLE 38 PDX MODELS MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
8.2 PRECLINICAL DRUG DEVELOPMENT
8.2.1 RISE IN NUMBER OF CLINICAL TRIALS WILL DRIVE THE GROWTH OF THIS SEGMENT
TABLE 39 PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 EUROPE: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 ASIA PACIFIC: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 BIOMARKER ANALYSIS
8.3.1 GROWING INTEREST IN PRECISION MEDICINE WILL CONTRIBUTE TO THE DEMAND FOR PDX MODELS FOR BIOMARKER ANALYSIS
TABLE 43 PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2019–2026 (USD MILLION)
TABLE 44 NORTH AMERICA: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 EUROPE: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 ASIA PACIFIC: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 BASIC CANCER RESEARCH
8.4.1 RISING FUNDING FOR CANCER RESEARCH WILL DRIVE MARKET GROWTH IN THIS SEGMENT
TABLE 47 PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 EUROPE: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 ASIA PACIFIC: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
9 PDX MODELS MARKET, BY END USER (Page No. - 84)
9.1 INTRODUCTION
TABLE 51 PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 RISING COLLABORATION BETWEEN PHARMA & BIOTECH COMPANIES FOR DEVELOPING CANCER THERAPEUTICS
TABLE 52 PDX MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 EUROPE: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 55 ASIA PACIFIC: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES WILL DRIVE MARKET GROWTH
TABLE 56 PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 57 NORTH AMERICA: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 EUROPE: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 59 ASIA PACIFIC: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTIONS
9.4.1 INCREASE IN GOVERNMENT LIFE SCIENCES R&D EXPENDITURE WILL CONTRIBUTE TO THE GROWTH OF THIS SEGMENT
TABLE 60 PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 EUROPE: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 ASIA PACIFIC: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
10 PDX MODELS MARKET, BY REGION (Page No. - 92)
10.2 NORTH AMERICA
TABLE 64 PDX MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: PDX MODELS MARKET SNAPSHOT
TABLE 65 NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Growing focus on cancer research in the US will drive market growth
TABLE 70 US: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 US: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 72 US: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 73 US: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Growth in Canada can be attributed to rising funding for stem cell research in the country
TABLE 74 CANADA: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 CANADA: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 76 CANADA: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 77 CANADA: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 78 EUROPE: PDX MODELS MARKET, BY COUNTRY/REGION, 2019–2026 (USD MILLION)
TABLE 79 EUROPE: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 EUROPE: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 81 EUROPE: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 82 EUROPE: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth
TABLE 83 GERMANY: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 GERMANY: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 85 GERMANY: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 86 GERMANY: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth
TABLE 87 UK: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 UK: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 89 UK: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 90 UK: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer research
TABLE 91 FRANCE: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 92 FRANCE: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 93 FRANCE: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 94 FRANCE: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 ROE
TABLE 95 ROE: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 ROE: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 97 ROE: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 98 ROE: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: PDX MODELS MARKET SNAPSHOT
TABLE 99 ASIA PACIFIC: PDX MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 100 ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 ASIA PACIFIC: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 102 ASIA PACIFIC: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 103 ASIA PACIFIC: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 The growing pharmaceutical industry and rising number of CROs in the country will drive market growth
TABLE 104 CHINA: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 CHINA: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 106 CHINA: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 107 CHINA: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Research collaborations and growing geriatric population—key growth drivers in Japan
TABLE 108 JAPAN: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 JAPAN: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 110 JAPAN: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 111 JAPAN: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 REST OF ASIA PACIFIC
TABLE 112 ROAPAC: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 ROAPAC: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 114 ROAPAC: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 115 ROAPAC: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET
TABLE 116 LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 LATIN AMERICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 118 LATIN AMERICA: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 119 LATIN AMERICA: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D
TABLE 120 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
TABLE 122 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 123 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 122)
11.1 OVERVIEW
11.2 MARKET EVALUATION FRAMEWORK
TABLE 124 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, JOINT VENTURES, AND COLLABORATIONS—THE MAJOR STRATEGIES ADOPTED BY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 25 PDX MODELS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 26 TOP MARKET PLAYERS DOMINATE THE PDX MODELS MARKET
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE
11.5.4 EMERGING COMPANIES
FIGURE 27 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT, 2020
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 28 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
11.7 COMPANY PRODUCT FOOTPRINT
TABLE 125 PRODUCT PORTFOLIO ANALYSIS: PDX MODELS MARKET (2020)
11.8 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 126 GEOGRAPHIC REVENUE MIX: PDX MODELS MARKET (2020)
11.9 COMPETITIVE SCENARIO
11.9.1 PDX MODELS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2018–FEBRUARY 2021
11.9.2 PDX MODELS MARKET: DEALS, JANUARY 2019–FEBRUARY 2021
11.9.3 PDX MODELS MARKET: OTHER DEVELOPMENTS, JANUARY 2018–FEBRUARY 2021
12 COMPANY PROFILES (Page No. - 133)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 KEY MARKET PLAYERS
12.1.1 JSR CORPORATION
FIGURE 29 JSR CORPORATION: COMPANY SNAPSHOT (2019)
12.1.2 WUXI APPTEC
FIGURE 30 WUXI APPTEC: COMPANY SNAPSHOT (2020)
12.1.3 THE JACKSON LABORATORY
FIGURE 31 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019)
12.1.4 CHARLES RIVER LABORATORIES
FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.5 CHAMPIONS ONCOLOGY
FIGURE 33 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2020)
12.1.6 ONCODESIGN
FIGURE 34 ONCODESIGN: COMPANY SNAPSHOT (2020)
12.1.7 ENVIGO
12.1.8 PHARMATEST SERVICES
12.1.9 HERA BIOLABS
12.1.10 EPO BERLIN-BUCH GMBH
12.1.11 XENTECH
12.1.12 UROSPHERE
12.2 OTHER PLAYERS
12.2.1 ABNOVA CORPORATION
12.2.2 GENESIS BIOTECHNOLOGY GROUP
12.2.3 EXPLORA BIOLABS
12.2.4 BIOCYTOGEN
12.2.5 LIVING TUMOR LABORATORY
12.2.6 BIODURO
12.2.7 ARAGEN LIFE SCIENCES W.E.F
12.2.8 SHANGHAI LIDE BIOTECH
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 166)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the patient-derived xenograft/PDX models market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the PDX models market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include the American Association for Cancer Research (AACR), American Veterinary Medical Association (AVMA), American Association for Laboratory Animal Science (AALAS), Food and Drug Administration (FDA), European Medicines Agency (EMA), EurOPDX, European Animal Research Association (EARA), Swiss Laboratory Animal Science Association (SGV), Animal Technology Institute Taiwan (ATIT), Asian Mouse Mutagenesis Resource Association (AMMRA), Australian Phenomics Network (APN), and Sao Paulo Research Foundation (FAPESP). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the PDX models market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the PDX models business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global PDX models market based on the type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall PDX models market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the PDX models market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Top Key Companies in Humanized Xenograft Models Market
- The Jackson Laboratory
- Charles River Laboratories International, Inc.
- Crown Bioscience, Inc.
- Champions Oncology, Inc.
- Taconic Biosciences, Inc.
- Envigo
- HuMurine Technologies, Inc.
- Hera Biolabs
- Biocytogen
- InVivo Biosystems
These companies offer a range of humanized xenograft models for preclinical research, including mice and rats with humanized immune systems, patient-derived xenograft (PDX) models, and genetically modified models. They also offer various services such as model development, efficacy testing, and pharmacokinetic studies.
Top Future Hypothetic Growth Opportunities for Humanized Xenograft Models Market
- Increasing demand for personalized medicine: With the growing focus on personalized medicine, the demand for humanized xenograft models is expected to increase. These models are used to develop and test new drugs and therapies that are tailored to the individual patient's needs. For example, in 2021, Crown Bioscience partnered with Biomere to develop new humanized mouse models for cancer research.
- Growing use of gene editing technologies: The use of gene editing technologies such as CRISPR/Cas9 is expected to drive the growth of the humanized xenograft models market in the future. These technologies can be used to create customized models with specific genetic mutations that closely mimic human diseases. In 2021, The Jackson Laboratory introduced new humanized mouse models for studying COVID-19, created using CRISPR/Cas9 gene editing technology.
- Advancements in imaging technologies: Advances in imaging technologies such as MRI and PET are expected to increase the demand for humanized xenograft models for preclinical imaging studies. These models can be used to study the progression of diseases and the effectiveness of new therapies in real-time. In 2020, Charles River Laboratories launched a new preclinical imaging facility to support research using humanized mouse models.
- Increasing focus on immuno-oncology research: The growing focus on immuno-oncology research is expected to drive the growth of the humanized xenograft models market. These models are used to study the interaction between the immune system and cancer cells, and to develop new immunotherapies for cancer treatment. In 2021, Champions Oncology expanded its humanized mouse model offerings for immuno-oncology research.
- Rising demand for regenerative medicine: The increasing demand for regenerative medicine is expected to drive the growth of the humanized xenograft models market. These models can be used to study the efficacy and safety of new cell-based therapies and tissue engineering techniques. In 2021, Taconic Biosciences launched new humanized mouse models for studying liver regeneration and transplantation.
Top Future Growth Use Cases of Humanized Xenograft Models Market
- Drug Development: Humanized xenograft models can be used in drug development and testing to assess the safety and efficacy of new drugs before they are tested in humans.
- Cancer Research: Humanized xenograft models can be used to study cancer biology and test new cancer therapies. By transplanting human cancer cells into animals, researchers can study the progression of cancer and test the effectiveness of different treatments.
- Infectious Disease Research: Humanized xenograft models can be used to study infectious diseases such as HIV, tuberculosis, and malaria. By transplanting human immune cells into animals, researchers can study how the human immune system responds to these diseases and test new treatments.
- Immunology: Humanized xenograft models can be used to study the human immune system and test new immunotherapies.
- Transplantation: Humanized xenograft models can be used to study organ transplantation and test new anti-rejection therapies.
Recent examples of growth use cases for humanized xenograft models include the use of these models in COVID-19 research to study the immune response to the virus and test new treatments. Additionally, humanized xenograft models have been used in recent years to develop new cancer immunotherapies, such as CAR-T cell therapies, that have shown promising results in clinical trials.
Industry Impact of Humanized Xenograft Models Market:
The humanized xenograft models market is likely to impact a range of industries that utilize preclinical research, drug discovery and development, and personalized medicine. Some of the key industries that could be impacted by the growth of the humanized xenograft models market include:
- Pharmaceutical and biotechnology companies: Humanized xenograft models can be used to evaluate the efficacy and safety of potential drugs, accelerating the drug development process and reducing costs.
- Contract research organizations (CROs): CROs can offer humanized xenograft models as a service to pharmaceutical and biotechnology companies for drug development and preclinical research.
- Academic and research institutions: Humanized xenograft models can be used in academic and research institutions for studying disease progression, drug screening, and testing.
- Diagnostic and imaging companies: Humanized xenograft models can be used to evaluate the efficacy and safety of imaging agents and diagnostics.
- Personalized medicine companies: Humanized xenograft models can be used to develop personalized medicine approaches by testing potential treatments on a patient's tumor cells grown in a mouse model.
- Medical device companies: Humanized xenograft models can be used to evaluate the safety and efficacy of medical devices, such as implantable sensors or drug delivery devices.
- Regenerative medicine companies: Humanized xenograft models can be used to evaluate the safety and efficacy of regenerative medicine therapies, such as stem cell treatments.
- Government and regulatory agencies: Humanized xenograft models can be used by regulatory agencies to evaluate the safety and efficacy of new drugs, devices, and therapies before they are approved for human use.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Growth opportunities and latent adjacency in Patient-Derived Xenograft/PDX Model Market